Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genmab A/S (GMAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Genmab files annual reports on Form 20‑F and furnishes current reports on Form 6‑K under the Securities Exchange Act of 1934. These filings cover a wide range of topics, from interim financial results and capital increases to equity awards, articles of association and material company announcements.
Recent Forms 6‑K referenced in the available data include interim reports, company announcements about net sales of partnered products such as DARZALEX, capital increases resulting from employee warrant exercises, grants of restricted stock units and warrants, and disclosures related to the proposed acquisition of Merus N.V. and associated financing. Other 6‑K filings incorporate company announcements on regulatory milestones for EPKINLY (epcoritamab‑bysp), portfolio prioritization decisions and updates on late‑stage clinical programs.
Because Genmab uses its 6‑K reports to furnish key announcements to U.S. investors, these filings can be a primary source for understanding changes in its capital structure, details of tender offers and acquisitions, and the status of important clinical and commercial programs. On Stock Titan, users can review these documents alongside AI‑powered summaries that explain the context and main points of each filing, helping to interpret technical content in forms such as 6‑K and 20‑F.
Investors researching GMAB can use this page to follow how Genmab reports on its antibody platforms, collaborations, late‑stage pipeline, financing arrangements and governance documents over time. The combination of real‑time EDGAR updates and AI‑generated insights is intended to make it easier to navigate lengthy filings and identify information relevant to Genmab’s business and capital markets activity.
Genmab A/S files an updated set of Articles of Association, outlining its capital structure, governance framework, and equity incentive authorizations. The company’s share capital is set at DKK 64,238,408, divided into shares of DKK 1.
The Board of Directors is authorized until March 12, 2029 to increase share capital by up to a nominal DKK 6,600,000, both with and without pre-emption rights. Separate authorizations allow issuance of employee warrants under several 750,000-warrant programs and convertible debt instruments convertible into up to nominal DKK 3,000,000 of new shares.
The Articles also formalize rules for general meetings, electronic communication with shareholders, employee representation on the Board, and an indemnification scheme for directors running until March 12, 2029, subject to exclusions for fraud, criminal offences, wilful misconduct, or gross negligence.
Genmab A/S has granted 32,806 restricted stock units (RSUs) and 34,307 warrants to employees of the company and its subsidiaries. Each RSU is awarded cost-free and gives a conditional right to one Genmab share of nominally DKK 1.
The fair value of each RSU equals the DKK 2,067 closing market price per Genmab share on the grant date. RSUs vest on the first banking day of the month following three years from grant, subject to conditions in the Board-approved RSU program.
Each warrant is also awarded cost-free, carries an exercise price of DKK 2,067 and entitles the holder to subscribe one share of nominally DKK 1. Using the Black-Scholes formula, the fair value of each warrant is DKK 658.81. Warrants vest after three years and expire seven years from grant under the company’s February 23, 2021 warrant program.
Genmab A/S reported that worldwide 2025 net trade sales of the cancer medicine DARZALEX (daratumumab), including the subcutaneous DARZALEX FASPRO formulation, were USD 14,351 million as reported by Johnson & Johnson. Net trade sales were USD 8,266 million in the U.S. and USD 6,085 million in the rest of the world. Genmab receives royalties on all worldwide net sales of both the intravenous and subcutaneous products under its exclusive license agreement with Johnson & Johnson. The filing also reiterates that Genmab is a biotechnology company focused on antibody-based medicines, with multiple approved therapies and a late-stage clinical pipeline.
Genmab A/S reported topline Phase 3 results from the EPCORE DLBCL-1 trial of epcoritamab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In 483 patients ineligible for high-dose chemotherapy and transplant, subcutaneous epcoritamab monotherapy improved progression-free survival with a hazard ratio of 0.74 (95% CI 0.60–0.92) versus chemotherapy. Complete response rate, duration of response and time to next treatment also improved with epcoritamab.
Overall survival showed a hazard ratio of 0.96 (95% CI 0.77–1.20) and did not reach statistical significance. The safety profile appeared consistent with known risks, including cytokine release syndrome, neurologic events, infections and low blood counts as highlighted in the EPKINLY prescribing information. Genmab and AbbVie plan to discuss these results with global regulators and expect additional Phase 3 data for fixed-duration epcoritamab regimens in DLBCL during 2026.
Genmab A/S reported changes in its beneficial ownership of Merus N.V. following a cash tender offer. Through its wholly owned subsidiary, Genmab Holding II B.V., it accepted 71,463,077 Merus common shares at $97.00 per share on December 12, 2025, representing about 94.2% of Merus’s outstanding common shares at that time. During a subsequent offering period, the purchaser acquired an additional 120,752 shares on December 16, 2025 and 150,795 shares on December 17, 2025. After these transactions, Genmab, as parent of the purchasing subsidiary, is reported as indirectly beneficially owning over 71.7 million Merus shares.
Genmab A/S has filed an initial ownership report showing it now beneficially owns 71,463,077 common shares of Merus N.V., indirectly through its wholly owned subsidiary Genmab Holding II B.V. These shares were acquired in a tender offer that expired on December 12, 2025.
The accepted shares represent approximately 94.2% of Merus’s outstanding common shares. Tendering shareholders received a cash payment of $97.00 per share, without interest and less applicable withholding taxes, giving Genmab effective control of nearly all of Merus’s equity.
Genmab A/S submitted a Form 6-K as a foreign private issuer, furnishing a company announcement dated November 20, 2025 about the grant of restricted stock units and warrants to employees of Genmab.
The report is also incorporated by reference into several existing Genmab Form S-8 registration statements, making the announcement part of those employee equity compensation registrations.
Genmab A/S filed a Form 6-K as a foreign private issuer to furnish a company announcement related to insider dealing disclosures. The filing incorporates this update by reference into several existing Form S-8 registration statements for the company’s equity compensation plans, meaning the information becomes part of those registration documents. The attached exhibit covers transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons.